In a pivotal ruling, the Supreme Court has upheld Maryland's ban on assault-style rifles, a significant victory for gun safety advocates. This decision reinforces state-level restrictions amidst ongoing debates over gun rights and safety.
In a surprising move, Harvey Weinstein will not testify at his New York retrial, leaving jurors to deliberate on the emotional testimonies of his accusers. Will his decision change the trial's outcome?
Donald Trump's administration seeks Supreme Court intervention to lift a ruling blocking mass job cuts across federal agencies, arguing it is within presidential authority. This follows a judge's decision siding with unions and local governments against the layoffs.
Robert F. Kennedy Jr. canceled a critical $766 million contract with Moderna for a bird flu vaccine, raising concerns about public health and vaccine safety amidst a potential outbreak.
In a bold move, Google plans to appeal a recent antitrust ruling that challenges its dominance in online search and advertising. The tech giant argues that the court's decision undermines competition. What's next for Google and the future of search?
In a surprising move, Trump has announced he will withdraw Jared Isaacman’s nomination to lead NASA, a choice backed by Elon Musk. What does this mean for the future of space exploration?
Analysts are revealing their positions on stocks like DHR and CNQ, but what does it mean for your investments? Discover the implications of these disclosures and how they can affect your financial decisions.
In a surprising move, the White House announced it will withdraw Jared Isaacman's nomination to lead NASA, just days before a Senate vote. The decision highlights the administration's focus on aligning NASA's leadership with Trump's America First agenda.
In a significant ruling, an appeals court has upheld an injunction preventing federal layoffs, rejecting the Trump administration's efforts to proceed with workforce reductions. This decision may lead to a Supreme Court showdown.
The Trump administration's sudden cancellation of a $258 million HIV vaccine research program has ignited outrage among scientists and public health advocates, jeopardizing years of progress in HIV prevention and treatment as infection rates surge.
